MDMA-assisted therapy for OCD in adults
Treatments studied
Part of Mental health clinical trials.
This trial tests whether MDMA plus cognitive behavioral therapy (CBT) can reduce OCD symptoms in adults who have tried standard OCD treatments before. You may be asked to pause certain medicines and follow specific diet/medication rules around the study session.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You need to be able to speak and read the main language used at the study site
- You must be able to swallow pills
- You must have an OCD diagnosis with a symptom severity score of 16 or higher
- You must not be taking “psychotropic” (mind/brain-altering) medications for at least 1 month before starting
- You must be able to take a medication-free period and complete all study appointments and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how ketamine may work quickly in people with obsessive-compulsive disorder (OCD), especially after at least one standard treatment didn’t help. If you join, you’ll need to follow study procedures like fasting before the experimental visit and not enrolling in other medication trials during the study.
This Phase 2 study tests whether psilocybin-assisted psychotherapy can reduce symptoms in adults with severe, treatment-resistant OCD. It also focuses on safety and whether this approach is practical to run.
This study tests if a single dose of psilocybin, a psychedelic substance, can safely help people with obsessive-compulsive disorder (OCD) who have not responded well to standard treatments. If you have moderate to severe OCD and have tried at least one recommended treatment without success, you may be able to join.
This trial studies whether adding structured talk therapy (CBT) can help some children with obsessive-compulsive disorder (OCD) reduce and potentially stop their OCD medicine. It’s designed for kids who are still having meaningful symptoms despite being on an OCD medication long enough.
This study tests a personalized brain-stimulation approach to help people with obsessive-compulsive disorder (OCD) focused on contamination worries. If you have the “contamination” type of OCD and meet the safety and medication rules, you may be able to join and see whether this targeted treatment reduces symptoms.
This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.
Hear when a new Obsessive-Compulsive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.